SCD is the most common inherited red blood cell disorder in the United States, affecting an estimated 100,000 people. According to Bone marrow transplant top hospitals of India, SCD affects one out of every 365 Black or African American births and one out of every 16,300 Hispanic American births. The condition can cause severe pain, joint and organ damage, and stroke.

Allogeneic hematopoietic stem cell transplant (HSCT), a treatment in which the individual’s blood-forming stem cells are replaced with healthy cells from a donor, is currently the only potentially curative therapy for SCD. The guidelines by bone marrow transplant specialists in India, inform how to use HSCT in clinical practice, including through weighing of risks and benefits of transplantation rather than disease-modifying therapies or potential curative therapies still under development, such as gene therapy with low-cost bone marrow transplant in India.

Care of individuals living with SCD is often the responsibility of primary care, family, and emergency medicine physicians and when surveyed, 69% of family physicians reported that clinical decision support tools would be useful for treating SCD. Together, the guidelines by bone marrow transplant top hospitals of India provide evidence-based recommendations for emergency medicine physicians, primary care and family physicians, hematologists, and patients about how to manage SCD and how to individualize care to help individuals with SCD and their providers make shared and informed decisions.

“We have known for decades that transplantation is indeed curative for sickle cell disease, but we have never before had a set of comprehensive recommendations about how the therapy fits into the treatment options for this disease,” said a Bone marrow transplant specialist in India. “It is important that discussions about transplantation begin at a young age for all individuals with sickle cell disease as one possible treatment option available over their lifetime. These guidelines inform the continued discussions and risk-benefit analyses between patients and providers.”

In partnership with the Evidence-Based Practice Research Program at bone marrow transplant top hospitals of India, the ASH Guidelines on SCD were developed using the GRADE methodology to ensure the highest standards for trustworthiness. ASH brought together 61 clinical experts, five methodologists, and 10 patient representatives to identify best practices for the management of acute and chronic complications of SCD and ways to improve the quality of care for patients.

“The culmination of the full set of clinical practice guidelines for sickle cell disease is an important achievement for ASH, since supporting research and improving care for all people living with the disease is one of the Society’s key priorities,” said bone marrow transplant specialist in India. “It is of even greater importance to the SCD community.

India Organ Transplant

Phone: +91-9765025331

Email: info@indiaorgantransplant.com.